Artivion (AORT): Evaluating Valuation Following Positive Clinical Trial Results for AMDS Hybrid Prosthesis

Simply Wall St.

Yesterday

Artivion (NYSE:AORT) just shared encouraging data from its AMDS PERSEVERE and PROTECT clinical trials at a key international conference. This drew attention to the performance of its AMDS Hybrid ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577333708"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577333708\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577333708?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2025-10-22 13:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577333708","market":"us","top_or_hot":-1,"title":"Artivion (AORT): Evaluating Valuation Following Positive Clinical Trial Results for AMDS Hybrid Prosthesis","media":"Simply Wall St.","content":"<div>\n<p>Artivion (NYSE:AORT) just shared encouraging data from its AMDS PERSEVERE and PROTECT clinical trials at a key international conference. This drew attention to the performance of its AMDS Hybrid ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-evaluating-valuation-following-positive-clinic\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artivion (AORT): Evaluating Valuation Following Positive Clinical Trial Results for AMDS Hybrid Prosthesis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtivion (AORT): Evaluating Valuation Following Positive Clinical Trial Results for AMDS Hybrid Prosthesis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-22 13:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-evaluating-valuation-following-positive-clinic><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Artivion (NYSE:AORT) just shared encouraging data from its AMDS PERSEVERE and PROTECT clinical trials at a key international conference. This drew attention to the performance of its AMDS Hybrid ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-evaluating-valuation-following-positive-clinic\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-evaluating-valuation-following-positive-clinic","article_id":"2577333708","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/artivion-aort-evaluating-valuation-following-positive-clinic","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2577333708","pubTimestamp":1761110614,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Artivion (NYSE:AORT) just shared encouraging data from its AMDS PERSEVERE and PROTECT clinical trials at a key international conference. This drew attention to the performance of its AMDS Hybrid Prosthesis in treating acute aortic dissection.\nSee our latest analysis for Artivion.\nArtivion’s latest clinical success comes as momentum builds in its share price. The latest close sits at $42.3, with a 90-day share price return of 35.4% and a one-year total shareholder return of 59.4%. These recent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","AORT":"Artivion","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","AMDS":"GRANITESHARES 1X SHORT AMD DAILY ETF","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC"},"translate_title":"Artivion(AORT)：AMDS混合假体临床试验结果积极后的估值评估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMDS":1.5,"AORT":1.5},"content_text":"Artivion (NYSE:AORT) just shared encouraging data from its AMDS PERSEVERE and PROTECT clinical trials at a key international conference. This drew attention to the performance of its AMDS Hybrid Prosthesis in treating acute aortic dissection. See our latest analysis for Artivion. Artivion’s latest clinical success comes as momentum builds in its share price. The latest close sits at $42.3, with a 90-day share price return of 35.4% and a one-year total shareholder return of 59.4%. These recent gains reflect growing optimism as the company delivers tangible clinical milestones while working towards regulatory approval, signaling renewed investor confidence in both its innovation and growth outlook. If this leap in medtech progress caught your attention, you’ll want to see other healthcare leaders making headlines. See the full list for free. With shares up sharply over the past year and strong clinical results driving momentum, investors now face a key question: is Artivion still undervalued, or is the market already pricing in its next phase of growth? AdvertisementMost Popular Narrative: 6.5% Undervalued With Artivion’s narrative fair value sitting above the latest close, the spotlight is now on what is fueling this bullish outlook and whether it is defendable amid heightened expectations.  Strong growth in constant currency revenue (14% YoY) and adjusted EBITDA (33% YoY), primarily driven by increasing adoption of innovative and clinically differentiated products like On-X valves and AMDS, positions Artivion to benefit from the rising need for heart valve replacements as the global population ages, supporting sustained revenue and earnings growth.  Read the complete narrative. Want to know what is behind this premium valuation? This narrative depends on rapid margin expansion, fast-growing sales, and an aggressive future earnings target. Which bold projections stand behind the consensus fair value? Read to see what numbers drive this call. Result: Fair Value of $45.26 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, risks remain, including uncertainty around future product adoption and the challenge of defending margins as competition increases and healthcare pricing pressures intensify. Find out about the key risks to this Artivion narrative. Another View: What Do Market Multiples Say? Looking at market ratios offers a different angle. Artivion’s current price-to-sales ratio is 4.9x, which stands well above both the US Medical Equipment industry average of 3.2x and peer average of 3.9x. Compared to the fair ratio of 2.8x, the company looks expensive on this measure. This suggests a risk if sentiment cools or expectations shift. Could investors be getting ahead of the fundamentals? See what the numbers say about this price — find out in our valuation breakdown. NYSE:AORT PS Ratio as at Oct 2025 Build Your Own Artivion Narrative If you see the story differently, or want to dig into the numbers and shape your own outlook, you can create a narrative in under three minutes. Do it your way. A great starting point for your Artivion research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision. Looking for More Investment Ideas? Smart investors never stop at one opportunity. Take your portfolio further by targeting powerful themes and sectors where upside potential could surprise you.  Capture the income advantage by targeting companies offering high yields. Start with these 17 dividend stocks with yields > 3% to boost your regular returns. Get ahead of the next tech wave and position yourself early with these 24 AI penny stocks leading groundbreaking advances in artificial intelligence. Spot untapped potential by considering these 877 undervalued stocks based on cash flows and uncover hidden gems trading below their true worth before the rest of the market catches on.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}